Investing.com – Incyte (NASDAQ:) reported on Tuesday fourth quarter that beat analysts’ forecasts and revenue that topped expectations.
Incyte announced earnings per share of $0.93 on revenue of $789.5M. Analysts polled by Investing.com anticipated EPS of $0.5346 on revenue of $659.5M.
Incyte shares are down 5.75% from the beginning of the year, still down 15.14% from its 52 week high of $110.32 set on July 7, 2020. They are under-performing the S&P 500 which is up 4.25% from the start of the year.
Incyte follows other major Healthcare sector earnings this month
Incyte’s report follows an earnings beat by J&J on January 26, who reported EPS of $1.86 on revenue of $22.48B, compared to forecasts EPS of $1.82 on revenue of $21.66B.
Roche Holding ADR had missed expectations on February 1 with fourth quarter EPS of $1.21 on revenue of $15.88B, compared to forecast for EPS of $1.28 on revenue of $16.45B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment